A study of enfortumab vedotin given in the bladder for treatment of patients with non-muscle invasive bladder cancer (NMIBC).

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503388-40-00

Acronym

SGN22E-004

Enrollment

Registered

2023-10-25

Start date

2021-08-24

Completion date

2025-09-22

Last updated

2025-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-muscle invasive bladder cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026